Human CD4+ T cells lyse target cells via granzyme/perforin upon circumvention of MHC class II restriction by an antibody-like immunoreceptor

Journal of Immunology

Volumn 177, Issue 8, 2006, Pages 5668-5675

  Hombach, Andreas ^a   Köhler, Heike ^a   Rappl, Gunter ^a   Abken, Hinrich ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CYTOKINE; DEATH RECEPTOR; FAS ANTIGEN; FC RECEPTOR; GRANZYME A; GRANZYME B; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PERFORIN; RECOMBINANT RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANTIGEN BINDING; ANTIGEN EXPRESSION; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL LINE; CELL STRAIN HEK293; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOLYSIS; HELPER CELL; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR CELL CULTURE;

EID: 33749519601     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.177.8.5668     Document Type: Article

References (32)

1. + T lymphocytes. Nature 421: 852-856.
2. Melief, C. J., R. E. Toes, J. P. Medema, S. H. van der Burg, F. Ossendorp, and R. Offringa. 2000. Strategies for immunotherapy of cancer. Adv. Immunol. 75: 235-282.
3. + T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-γ. Proc. Natl. Acad. Sci. USA 96: 8633-8638.
4. + T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFNγ receptor expression by nonhematopoietic cells. Immunity 12: 677-686.
5. Eshhar, Z., T. Waks, G. Gross, and D. G. Schindler. 1993. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the γ or ζ subunits of the immunoglobulin and T-cell receptors. Proc. Natl. Acad. Sci. USA 90: 720-724.
6. Moritz, D., W. Wels, J. Mattern, and B. Groner. 1994. Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB2-expressing tumor cells. Proc. Natl. Acad. Sci. USA 91: 4318-4322.
7. Hwu, P., J. C. Yang, R. Cowherd, J. Treisman, G. E. Shafer, Z. Eshhar, and S. A. Rosenberg. 1995. In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes. Cancer Res. 55: 3369-3373.
8. Abken, H., A. Hombach, U. Reinhold, and S. Ferrone. 1998. Can combined T-cell- and antibody-based immunotherapy outsmart tumor cells? Immunol. Today 19: 2-5.
9. + T cells engrafted with a recombinant immunoreceptor efficiently lyse target cells in a MHC antigen- and Fas-independent fashion. J. Immunol. 167: 1090-1096.
10. + T cells after redirection of their specificity by a high-affinity p53A2.1-specific TCR. Immunity 22: 117-129.
11. Watanabe-Fukunaga, R., C. I. Brannan, N. G. Copeland, N. A. Jenkins, and S. Nagata. 1992. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 356: 314-317.
12. Takahashi, T., M. Tanaka, C. I. Brannan, N. A. Jenkins, N. G. Copeland, T. Suda, and S. Nagata. 1994. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell 76: 969-976.
13. Walsh, C. M., M. Matloubian, C. C. Liu, R. Ueda, C. G. Kurahara, J. L. Christensen, M. T. Huang, J. D. Young, R. Ahmed, and W. R. Clark. 1994. Immune function in mice lacking the perforin gene. Proc. Natl. Acad. Sci. USA 91: 10854-10858.
14. Braun, M. Y., B. Lowin, L. French, H. Acha-Orbea, and J. Tschopp. 1996. Cytotoxic T cells deficient in both functional fas ligand and perforin show residual cytolytic activity yet lose their capacity to induce lethal acute graft-versus-host disease. J. Exp. Med. 183: 657-661.
15. Shresta, S., C. T. Pham, D. A. Thomas, T. A. Graubert, and T. J. Ley. 1998. How do cytotoxic lymphocytes kill their targets? Curr. Opin. Immunol. 10: 581-587.
16. Graubert, T. A., J. F. DiPersio, J. H. Russell, and T. J. Ley. 1997. Perforin/granzyme-dependent and independent mechanisms are both important for the development of graft-versus-host disease after murine bone marrow transplantation. J. Clin. Invest. 100: 904-911.
17. Darcy, P. K., N. M. Haynes, M. B. Snook, J. A. Trapani, L. Cerruti, S. M. Jane, and M. J. Smyth. 2000. Redirected perforin-dependent lysis of colon carcinoma by ex vivo genetically engineered CTL. J. Immunol. 164: 3705-3712.
18. + cytotoxic T lymphocytes in humans. Blood 95: 2352-2355.
19. Kaulen, H., G. Seemann, K. Bosslet, W. Schwaeble, and W. Dippold. 1993. Humanized anti-carcinoembryonic antigen antibody: strategies to enhance human tumor cell killing. Year Immunol. 7: 106-109.
20. Weijtens, M. E., R. A. Willemsen, E. H. Hart, and R. L. Bolhuis. 1998. A retroviral vector system "STITCH" in combination with an optimized single chain antibody chimeric receptor gene structure allows efficient gene transduction and expression in human T lymphocytes. Gene Ther. 5: 1195-1203.
21. Hombach, A., D. Koch, R. Sircar, C. Heuser, V. Diehl, W. Kruis, C. Pohl, and H. Abken. 1999. A chimeric receptor that selectively targets membrane-bound carcinoembryonic antigen (mCEA) in the presence of soluble CEA. Gene Ther. 6: 300-304.
22. Hombach, A., C. Schneider, D. Sent, D. Koch, R. A. Willemsen, V. Diehl, W. Kruis, R. L. Bolhuis, C. Pohl, and H. Abken. 2000. An entirely humanized CD3 ζ-chain signaling receptor that directs peripheral blood t cells to specific lysis of carcinoembryonic antigen-positive tumor cells. Int. J. Cancer 88: 115-120.
23. Hombach, A., C. Heuser, M. Gerken, B. Fischer, K. Lewalter, V. Diehl, C. Pohl, and H. Abken. 2000. T cell activation by recombinant FcεRI γ-chain immune receptors: an extracellular r domain impairs antigen-dependent T cell activation but not antigen recognition. Gene Ther. 7: 1067-1075.
24. Jost, L. M., J. M. Kirkwood, and T. L. Whiteside. 1992. Improved short- and long-term XTT-based colorimetric cellular cytotoxicity assay for melanoma and other tumor cells. J. Immunol. Methods 147: 153-165.
25. Provinciali, M., G. Di Stefano, and N. Fabris. 1992. Optimization of cytotoxic assay by target cell retention of the fluorescent dye carboxyfluorescein diacetate (CFDA) and comparison with conventional 51CR release assay. J. Immunol. Methods 155: 19-24.
26. Angulo, R., and D. A. Fulcher. 1998. Measurement of Candida-specific blasto-genesis: comparison of carboxyfluorescein succinimidyl ester labelling of T cells, thymidine incorporation, and CD69 expression. Cytometry 34: 143-151.
27. + cytotoxic T lymphocyte-mediated lysis. J. Immunol. 150: 4303-4314.
28. + cytotoxic T-lymphocyte clones. J. Virol 73: 3623-3629.
29. + T lymphocytes in an HLA class II-restricted manner. Blood 106: 1415-1418.
30. Hsieh, M. H., and R. Korngold. 2000. Differential use of FasL- and perforin-mediated cytolytic mechanisms by T-cell subsets involved in graft-versus-myeloid leukemia responses. Blood 96: 1047-1055.
31. + T cell-mediated insulin-dependent diabetes mellitus. J. Immunol. 163: 4335-4341.
32. + cytotoxic T lymphocytes. Exp. Hematol. 33: 811-818.